🇺🇸 FDA
Patent

US 7982011

Mutated anti-cd22 antibodies and immunoconjugates

granted A61KA61K47/6829A61K47/6849

Quick answer

US patent 7982011 (Mutated anti-cd22 antibodies and immunoconjugates) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Jul 14 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Jul 19 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 14 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
40
CPC classes
A61K, A61K47/6829, A61K47/6849, A61P, A61P35/00